Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 6:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 283 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Diffuse Large B-Cell Lymphoma (DLBCL) Clear all
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
bortezomib, dexamethasone, ifosfamide, mesna, cisplatin, etoposide, rituximab
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced May 21, 2026, 6:19 PM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Epcoritamab, Investigator's Choice Chemotherapy
Biological · Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
15
States / cities
Indianapolis, Indiana • Lexington, Kentucky • Jackson, Michigan + 10 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced May 21, 2026, 6:19 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Maplirpacept, Tafasitamab, Lenalidomide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Baton Rouge, Louisiana • Ann Arbor, Michigan • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced May 21, 2026, 6:19 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL), Lymphoma, Large B-Cell, Diffuse (DLBCL), Chronic Lymphocytic Leukemia (CLL)
Interventions
UB-VV111, rapamycin
Genetic · Drug
Lead sponsor
Umoja Biopharma
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
Duarte, California • Chicago, Illinois • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced May 21, 2026, 6:19 PM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Epcoritamab, Cyclophosphamide, Rituximab, Vincristine, Doxorubicin, Prednisone
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years to 79 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
68
States / cities
Tucson, Arizona • Yuma, Arizona • Little Rock, Arkansas + 57 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced May 21, 2026, 6:19 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Neoplasms
Interventions
Qualitative Interviews, PROMIS Physical Function Items
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Mountlake Terrace, Washington
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced May 21, 2026, 6:19 PM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Interventions
Blinatumomab, Pembrolizumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
La Jolla, California • Charleston, South Carolina • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced May 21, 2026, 6:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma
Interventions
Revlimid
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Hackensack, New Jersey • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced May 21, 2026, 6:19 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
CD20 Positive, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions
Carboplatin, Etoposide, Ibrutinib, Ifosfamide, Laboratory Biomarker Analysis, Pharmacological Study, Rituximab
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced May 21, 2026, 6:19 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Lymphoma
Interventions
Lenalidomide, Vorinostat, Gemcitabine, Busulfan, Melphalan, Rituximab, Dexamethasone, Caphosol, Glutamine, Pyridoxine, Enoxaparin, Stem Cell Transplant, Palifermin
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced May 21, 2026, 6:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Lymphoma
Interventions
Flavopiridol
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 29, 2018 · Synced May 21, 2026, 6:19 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Relapsed/Refractory B-cell Lymphomas, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Chronic Lymphocytic Leukemia (CLL), Marginal Zone Lymphoma (MZL), Mantle Cell Lymphoma (MCL), Small Lymphocytic Lymphoma (SLL), Primary Mediastinal Large B Cell Lymphoma, Transformed Follicular Lymphoma, Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma, Burkitt Lymphoma
Interventions
CLBR001 and SWI019
Combination Product
Lead sponsor
Calibr, a division of Scripps Research
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
8
States / cities
Duarte, California • San Diego, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced May 21, 2026, 6:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Lymphoma Follicular
Interventions
Atezolizumab, Bendamustine, Cyclophosphamide, Doxorubicin, Obinutuzumab, Prednisone, Vincristine, Rituximab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
9
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 23, 2021 · Synced May 21, 2026, 6:19 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Gastric Carcinoma, Gastroesophageal Junction Carcinoma, Classical Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma, Peripheral T-cell Lymphoma, Cutaneous Melanoma, Head and Neck Squamous Cell Carcinoma, Bladder Cancer, Ovarian Cancer, Triple Negative Breast Cancer, Cervical Cancer
Interventions
SEA-TGT, sasanlimab, brentuximab vedotin
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
26
States / cities
Birmingham, Alabama • Tucson, Arizona • Duarte, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced May 21, 2026, 6:19 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma
Interventions
Loncastuximab Tesirine
Drug
Lead sponsor
ADC Therapeutics S.A.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Lynwood, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced May 21, 2026, 6:19 PM EDT
Not listed Phase 1 Interventional
View directory record Official record
Conditions
NHL, Relapsed, Adult, B-cell Lymphoma, B-cell Leukemia, DLBCL - Diffuse Large B Cell Lymphoma, ALL, Adult B Cell, ALL, Childhood, CLL/SLL
Interventions
KUR-502
Genetic
Lead sponsor
Athenex, Inc.
Industry
Eligibility
3 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
San Francisco, California • Portland, Oregon • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced May 21, 2026, 6:19 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Lymphoma, Diffuse Large B-Cell
Interventions
PNT2258
Drug
Lead sponsor
Sierra Oncology LLC - a GSK company
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
26
States / cities
Long Beach, California • Los Angeles, California • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced May 21, 2026, 6:19 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional
View directory record Official record
Conditions
Relapsed/Refractory Diffuse Large B-cell Lymphoma
Interventions
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
8
States / cities
Chandler, Arizona • Tucson, Arizona • Cerritos, California + 4 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced May 21, 2026, 6:19 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma
Interventions
Blinatumomab, Autologous stem cell transplant, Carmustine, Etoposide, Cytarabine, Melphalan, Peripheral blood draws
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced May 21, 2026, 6:19 PM EDT
Not listed Phase 2 Interventional
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma
Interventions
Carboplatin, Ifosfamide, Etoposide, Rituximab, Carmustine, Cytarabine, Melphalan, Autologous HSCT, Acalabrutinib
Drug · Biological · Other
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced May 21, 2026, 6:19 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Acute Myeloid Leukemia, Multiple Myeloma, Diffuse Large B-cell Lymphoma
Interventions
MEDI7247
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 100 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
10
States / cities
Los Angeles, California • Denver, Colorado • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced May 21, 2026, 6:19 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Hematologic Cancer
Interventions
ABBV-101
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
14
States / cities
Tempe, Arizona • Orange, California • Palo Alto, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced May 21, 2026, 6:19 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Everolimus, rituximab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 26, 2014 · Synced May 21, 2026, 6:19 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma
Interventions
mosunetuzumab, glofitamab, obinutuzumab
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Omaha, Nebraska • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced May 21, 2026, 6:19 PM EDT